Back-to-back wins from TEDCO and the NSF are giving a Frederick startup the runway to prove that cartilage regeneration is possible — not just theoretical.
A Frederick, Maryland-based regenerative medicine company is having a strong summer.
Stemora Inc., which is developing therapies that coax the body’s own stem cells into rebuilding damaged cartilage, has landed two significant wins within weeks of each other: a $25,000 investment from TEDCO’s Pre-Seed Rural Business Innovation Initiative (RBII) Fund and a $305,000 Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation.
A Different Approach to Osteoarthritis
Most current treatments for osteoarthritis focus on managing pain rather than addressing the underlying joint damage — think long-term medication, complex cell-based procedures, or, in advanced cases, partial or total joint replacement. Stemora is trying to change that equation.
The company is building a one-step, intraoperative regenerative therapy intended to restore durable hyaline cartilage by activating the body’s own skeletal stem cells, using a modular, controlled-release biomaterial system designed to create a pro-regenerative environment directly inside cartilage defects.
NSF Backs the Science
The NSF SBIR Phase I grant, announced June 25, will help Stemora move its biomaterial delivery platform forward and test its regenerative potential in translational preclinical models — a step the company says positions it for future development milestones and additional funding down the road.
Founder and CEO Dr. Srujana Cherukuri was direct about what the recognition means for the company’s trajectory:
“We are honored to receive NSF’s support as we work to transform the treatment landscape for cartilage injuries. This recognition validates our scientific approach and accelerates our mission to deliver a regenerative therapy that restores joint function and improves quality of life for millions of patients.”
SBIR awards are notoriously competitive and are often treated by investors as a strong external signal that the underlying science holds up to scrutiny, since proposals go through rigorous federal peer review before money changes hands.
TEDCO Doubles Down on Rural Maryland Innovation
Two weeks earlier, on June 10, TEDCO — Maryland’s state-backed economic development engine for technology and life science companies — announced its own vote of confidence: a $25,000 investment through the RBII Fund, a program built specifically to support early-stage companies based in rural parts of the state. TEDCO pairs each region with a dedicated mentor who evaluates prospective portfolio companies and connects them with consulting and technical management resources.
Graham Dodge, TEDCO’s vice president of Venture Development, pointed to the RBII program as a key part of the state’s broader innovation ecosystem, saying it helps ensure “innovation can be found across the state.”
This isn’t TEDCO’s first bet on Stemora. The company joined TEDCO’s portfolio in 2025 after receiving Commercialization Fund support from the Maryland Stem Cell Research Fund (MSCRF) — a program that has awarded more than 640 grants since its 2007 inception, generating upwards of $19.2 million in state and local tax revenue.
Part of a Bigger Maryland Story
Stemora’s momentum lands squarely within a narrative Maryland officials have been eager to tell: that the state is a genuine hub for stem cell and regenerative medicine work, backed by a dense biopharma cluster, more than 70 federal laboratories, and a deep bench of university researchers.
For a company like Stemora — young, rural-based, and working in a cutting-edge therapeutic space — the combination of state-level and federal validation suggests it’s finding real traction as it moves its cartilage regeneration platform toward the clinic.
With both the TEDCO investment and the NSF grant now in hand, Stemora appears to be building the kind of layered funding base — state, federal, and eventually private — that early-stage biotech companies typically need to carry a therapy from bench to bedside. Whether the company’s regenerative approach can ultimately deliver on its promise of reversing cartilage degeneration, rather than just slowing it, will depend on the preclinical results this new NSF funding is meant to generate.
